#United States #Vista #Digital Pathology #Leica Biosystems #Aperio HALO AP

Leica Biosystems Expands Digital Pathology Offerings at Pathology Visions 2025

In the realm of digital pathology, Leica Biosystems is making headlines by unveiling multiple state-of-the-art solutions at the renowned Pathology Visions 2025. This significant event took place on October 1, 2025, where the company showcased its innovative tools aiming to transform the pathology landscape. The star attraction was the Aperio HALO AP, a cutting-edge AI-driven image management platform designed for streamlined integration of digital slides and data.

The Aperio HALO AP allows users to review images swiftly on an intuitive interface, which not only enhances the ease of use but also fosters collaboration and live conferencing. This sophisticated platform positions itself as a game-changer in facilitating an efficient workflow within pathology labs, responding to the growing demands for quick and accurate diagnostics.

In addition to HALO AP, Leica introduced the Aperio AI Store, which operates exclusively through the HALO AP platform. This scalable analytics tool incorporates numerous powerful applications developed in collaboration with various innovation partners such as Deep Bio and Histofy, creating an integrated solution for users.

Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems, emphasized that presenting these solutions is not merely about launching products. It symbolizes a major step toward the company’s commitment to Transforming Pathology, Together. He noted the overwhelming choice faced by users in the digital pathology world and highlighted how their commitment to interoperability aims to simplify the user experience by combining multiple solutions into a single interface.

Furthermore, collaboration with other industry leaders, such as Indica Labs, enhances the technological advancements made in computational pathology. Steven Hashagen, CEO of Indica Labs, pointed out the immense potential these innovations represent in elevating diagnostic accuracy and ushering in personalized patient care.

For pharmaceutical companies in need of AI-assisted diagnostics, Leica Biosystems offers the unique opportunity to develop custom AI applications within the Aperio AI Store. This open and flexible platform not only promotes seamless integration but empowers partners to streamline their development processes.

Leica also showcased additional innovative products at the event:

• - Aperio GT 450: This advanced brightfield scanner excels in functionality, enabling accurate imaging of various samples.
• - Aperio GT 180: Designed for high-speed, high-quality scanning, ideal for busy labs.
• - Aperio iQC: An AI-powered automated quality control software to ensure consistent and standardized whole slide imaging (WSI).
• - Aperio FL 120: A versatile scanner that supports brightfield, fluorescent, and FISH scanning for diverse research needs.
• - HALO Link: An innovative study-centric information management system employed globally in research environments.

While the Aperio HALO AP is designated for research purposes in the United States, it is notable for its CE IVDR-marking for in-vitro diagnostic use in other markets. Not all the showcased solutions may be available everywhere, nevertheless, the promising advancements highlight Leica Biosystems’ role as a leader in cancer diagnostic technologies.

In conclusion, Leica Biosystems is not just transforming its portfolio but is also redefining the digital pathology game, offering unprecedented solutions that promise not only to advance the accuracy of diagnostics but also to enhance the way pathologists interact and collaborate in their essential work. As a subsidiary of Danaher Corporation, the company is poised to continue pushing the boundaries of medical technology, with the mission of improving lives through advanced diagnostics.

For further information and a demonstration of these innovative solutions, attendees were invited to visit booth #313 during the Pathology Visions 2025 conference.